Trials / Completed
CompletedNCT01919827
Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis. Primary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients with mild-to-moderate idiopathic pulmonary fibrosis. Secondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Endobronchial infusion of adult mesenchymal stem cells | |
| BIOLOGICAL | Autologous mesenchymal stem cells derived from bone marrow |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2013-08-09
- Last updated
- 2018-05-03
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01919827. Inclusion in this directory is not an endorsement.